Janus Henderson Group PLC Trims Holdings in Progyny, Inc. (NASDAQ:PGNY)

Janus Henderson Group PLC reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 29.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 343,238 shares of the company's stock after selling 146,139 shares during the quarter. Janus Henderson Group PLC owned approximately 0.40% of Progyny worth $5,922,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PGNY. River Road Asset Management LLC purchased a new position in Progyny during the 4th quarter valued at $25,529,000. Pacer Advisors Inc. increased its position in Progyny by 47.5% during the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after purchasing an additional 1,183,558 shares during the period. Fort Washington Investment Advisors Inc. OH increased its position in Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. Barclays PLC boosted its holdings in shares of Progyny by 95.7% during the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock valued at $23,843,000 after buying an additional 676,048 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new stake in shares of Progyny during the 4th quarter valued at $11,265,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of research reports. Canaccord Genuity Group dropped their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Bank of America boosted their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a report on Monday, March 31st. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $23.45.

Progyny Price Performance

Progyny stock traded down $0.37 during mid-day trading on Friday, reaching $20.52. The stock had a trading volume of 822,500 shares, compared to its average volume of 1,710,099. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 2.39 and a beta of 1.37. The company has a 50-day moving average price of $22.15 and a two-hundred day moving average price of $19.93. Progyny, Inc. has a one year low of $13.39 and a one year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny's revenue was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.17 EPS. On average, equities research analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.